| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
CEO | Director
2 companies
Stephen Davis last filed a Form 4 in August 2024, as CEO at ACAD. The filings on record cover 2 companies. From October 2019 to August 2024, the filings on record show 0 open-market purchases and 27 sales. Stephen Davis's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Stephen Davis's trades have earned a middling insider score of 68/100 across 21 rated trades. Over a 12-month horizon, 76.2% of those trades were profitable, with an average 12-month return of +7.7%.
At the last filing, the largest reported position was 186,555 shares of ACAD. The ACAD filings lean toward selling, a net 901,217 shares.
Shares as reported in the last Form 4 for each company; the most recent is from August 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 6, 2023 | ACAD Acadia Pharmaceuticals Inc | CEO | Sale+OE | 8,582 | $18.16 | $155,849.12 | -7.9% | +31.7% | -1.9% | |
| Feb 24, 2023 | ACAD Acadia Pharmaceuticals Inc | CEO | Sale+OE | 3,851 | $18.78 | $72,321.78 | -4.0% | +29.2% | +31.0% | |
| Jan 9, 2023 | ACAD Acadia Pharmaceuticals Inc | CEO | Sale+OE | 3,904 | $17.13 | $66,876.69 | -4.4% | +5.6% | +81.9% | |
| Oct 15, 2022 | ACAD Acadia Pharmaceuticals Inc | CEO | Sale+OE | 2,804 | $15.81 | $44,331.24 | -3.4% | +17.0% | +51.3% | |
| May 2, 2022 | ACAD Acadia Pharmaceuticals Inc | CEO | Sale+OE | 5,483 | $18.18 | $99,691.36 | -6.7% | -27.8% | +9.4% | |
| Feb 23, 2022 | ACAD Acadia Pharmaceuticals Inc | CEO | Sale+OE | 3,928 | $23.80 | $93,486.40 | -5.6% | -35.3% | -22.6% | |
| Jan 6, 2022 | ACAD Acadia Pharmaceuticals Inc | CEO | Sale+OE | 3,718 | $23.05 | $85,699.90 | -6.0% | +16.4% | -26.0% | |
| Oct 18, 2021 | ACAD Acadia Pharmaceuticals Inc | CEO | Sale+OE | 2,963 | $17.41 | $51,585.83 | -5.3% | +19.0% | -8.9% | |
| Apr 30, 2021 | ACAD Acadia Pharmaceuticals Inc | CEO | Sale+OE | 7,850 | $20.33 | $159,590.50 | -13.7% | +8.4% | -10.3% | |
| Feb 4, 2021 | ACAD Acadia Pharmaceuticals Inc | CEO | Sell | 14,195 | $50.61 | $718,408.95 | -32.9% | -62.2% | -54.0% |